1.3.2 Second generation(第二代) 为了增强CAR T细胞的功能,第二代CAR在第一代的基础上增加了共刺激信号域(如CD28或4-1BB)。这种设计显著提高了CAR T细胞的增殖能力、细胞因子分泌和持久性。与CD28信号域相比,4-1BB信号域的CAR T细胞在体内具有更长的持久性和更低的激活诱导细胞死亡(AICD)风险,但CD28信号域...
synthetic receptors comprised of antigen recognition, signaling, and costimulatory domains are used to reprogram T-cells to target tumor cells for destruction. Despite the success of this approach in refractory B-cell malignancies, optimal potency of CAR T-cell therapy for ...
近日,由斯坦福大学医学院Crystal L. Mackall团队发表于Cancer Cell的题为Inosine induces stemness features in CAR-T cells and enhances potency 的文章,发现通过直接补充或过表达腺苷脱氨酶,可增加肌苷(INO)水平,从而增强CAR-T细胞的功能和干性。 首先,CD39是CAR-T细胞功能减弱的标志。大量耗竭的CD39+ CAR-T细胞...
van der Stegen, S.J.C., Lindenbergh, P.L., Petrovic, R.M.et al.Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells.Nat. Biomed. Eng6, 1284–1297 (2022). https://doi.org/10.1038/s41551-022-00915-0 ...
First, we sought to optimize the protocol for producing non-viral, gene-specific integrated T cells. A homology-directed repair (HDR) template, in the form of linear double-stranded DNA (dsDNA), was found to achieve high homologous recombination efficiency and cell viability (Fig.1aand Extended...
1、Garcia J, Daniels J, Lee Y, et al. Naturally occurring T cell mutations enhance engineered T cell therapies[J]. Nature, 2024: 1-9. 2、Somboonpatarakun C, Phanthaphol N, Suwanchiwasiri K, et al. Cytotoxicity of fourth-generation anti-Trop2 CAR-T cells against breast cancer[J]. ...
The application of chimeric antigen receptor (CAR) T cells in the management of hematological malignancies has emerged as a noteworthy therapeutic breakthrough. Nevertheless, the utilization and effectiveness of CAR-T cell therapy in solid tumors are sti
2022年3月29日,北京大学药学院刘涛课题组在Cell旗下的STAR Protocols杂志在线发表了题为“Efficient generation of locus-specific human CAR-T cells with CRISPR/cCas12a”的研究方案论文,利用其所开发的cCas12a基因编辑系统[1]进行了基因组定点整合的CAR-T细胞的高效制备。在此之前,刘涛课题组围绕基因编辑技术中存...
1、Garcia J, Daniels J, Lee Y, et al. Naturally occurring T cell mutations enhance engineered T cell therapies[J]. Nature, 2024: 1-9. 2、Somboonpatarakun C, Phanthaphol N, Suwanchiwasiri K, et al. Cytotoxicity of fourth-generation anti-Trop2 CAR-T cells against breast cancer[J]. ...
CAR-T细胞疗法已被批准用于治疗血癌,但该疗法在实体瘤方面的应用还很有限。实体瘤含有混合的细胞群,使得一些癌细胞即使在接受CAR-T细胞治疗后仍能继续躲避免疫系统的检测。 一个旨在为患有一种致命脑癌的患者带来细胞疗法的合作项目在首批接受这种新型疗法的患者中取得了显著效果。在一篇于2024年3月13日在线发表在New...